StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.89+0.22 (+1.61%)

Close on Nov 18, 2026Market cap $340.38MP/E –Yield –

Lyell Immunopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Lyell Immunopharma's operating income for the twelve months ending Jun 30, 2026 was -$256.50M. For fiscal 2025 it was -$269.40M. The highest annual figure on record is -$102.09M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$269.40M–
FY2024Dec 31, 2024-$358.76M–
FY2023Dec 31, 2023-$247.01M–
FY2022Dec 31, 2022-$187.06M–
FY2021Dec 31, 2021-$214.78M–
FY2020Dec 31, 2020-$211.94M–
FY2019Dec 31, 2019-$102.09M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$47.34M–
Q1 FY2026Mar 31, 2026-$44.26M–
Q4 FY2025Dec 31, 2025-$127.64M–
Q3 FY2025Sep 30, 2025-$37.25M–
Q2 FY2025Jun 30, 2025-$47.14M–
Q1 FY2025Mar 31, 2025-$57.37M–
Q4 FY2024Dec 31, 2024-$201.15M–
Q3 FY2024Sep 30, 2024-$50.51M–
Q2 FY2024Jun 30, 2024-$51.53M–
Q1 FY2024Mar 31, 2024-$55.58M–
Q4 FY2023Dec 31, 2023-$59.51M–
Q3 FY2023Sep 30, 2023-$59.04M–
Q2 FY2023Jun 30, 2023-$65.91M–
Q1 FY2023Mar 31, 2023-$62.56M–
Q4 FY2022Dec 31, 2022-$14.78M–
Q3 FY2022Sep 30, 2022-$66.44M–
Q2 FY2022Jun 30, 2022-$37.26M–
Q1 FY2022Mar 31, 2022-$68.58M–
Q4 FY2021Dec 31, 2021-$47.54M–
Q3 FY2021Sep 30, 2021-$49.16M–
Q2 FY2021Jun 30, 2021-$62.71M–
Q1 FY2021Mar 31, 2021-$55.37M–
Q4 FY2020Dec 31, 2020-$39.52M–
Q3 FY2020Sep 30, 2020-$36.84M–
Q2 FY2020Jun 30, 2020-$102.57M–

More Lyell Immunopharma figures

See a number that looks wrong?